CROI 2015 Program and Abstracts

Disclosure Information

DISCLOSURE INFORMATION

Disclosure information is presented as submitted by the corresponding author.

The authors listed below are the contact author for their presentations and have provided all relevant disclosures for themselves, their spouses, and their institution. In the event that an alternate author will be making the presentation, all relevant disclosures have also been provided for the alternate author, the alternate author’s spouse, and the alternate author’s institution. Alland, David Self: Cepheid: Grants/grants pending; Cepheid: Royalties Institution: Rutgers University: Cepheid: Royalties Amico, Rivet Self: Gilead: Grants/grants pending Arenas-Pinto, Alejandro Self: Janssen: Payment for development of education presentations; Janssen: Grants/grants pending; BMS: Grants/ grants pending Bhattacharya, Debika Self: Bristol Myers Squibb: Other; AbbVie: Other Bichoupan, Kian Self: Janssen: Consulting or advisor fee Blaschke, Terrence Cashin, Kieran Self: ViiV Healthcare: Other: honoraria fromViiV Healthcare Australia for conference travel Castel, Amanda Self: Gilead Sciences: Stock/stock options Castillo-Mancilla, Jose Self: Other: Study drug and contract work Ceccherini-Silberstein, Francesca

Self: Durect Corporation: Board Membership; MWV Healthcare: Other; Proteus Digital Health: Consulting or advisor fee; Guthy Jackson Charitable Foundation: Consulting or advisor fee Boeree, Martin Institution: University of Munich: Sequella: Provision of medicines, equipment, or administrative support Boesecke, Christophe Self: AbbVie, BMS, Gilead, MSD, Janssen,ViiV: Payment directly from commercial firms for lecture(s), including service on speakers’bureaus Boffito, Marta Self: BMS: Consulting or advisor fee;ViiV: Consulting or advisor fee;ViiV: Grants/grants pending; Gilead: Payment for development of education presentations; Gilead: Consulting or advisor fee; Janssen: Consulting or advisor fee Boyd, Mark Self: AbbVie: Grants/grants pending; Gilead Sciences: Board Membership; Merck: Grants/grants pending; Janssen-Cilag: Payment for development of education presentations; Bristol Myers Squibb: Payment for development of education presentations; Boehringer Ingelheim: Payment for development of education presentations Brady, Kathleen Self: Gilead: Payment directly from commercial firms for lecture(s), including service on speakers’bureaus; Gilead Sciences: Grants/grants pending Brew, Bruce Self: ViiV Healthcare Australia: Grants/grants pending;ViiV Healthcare Australia: Payment for development of education presentations Brown, Robert Self: AbbVie, BMS, Gilead, Janssen, Merck: Grants/grants pending; AbbVie, BMS, Gilead, Janssen, Merck: Consulting Self: AbbVie: Consulting or advisor fee; Merck: Board Membership; Gilead: Consulting or advisor fee;ViiV Healthcare: Consulting or advisor fee; EMD-Serono: Board Membership;Theratechnologies: Consulting or advisor fee Butt, Adeel Self: Merck, Gilead: Grants/grants pending Callebaut, Christian Self: Gilead: Employment; Gilead: Stock/stock options or advisor fee Brown, Todd

Self: Merck Sharp & Dohme: Grants/grants pending; Merck Sharp & Dohme,ViiV Healthcare, Gilead : Consulting or advisor fee;ViiV Healthcare - Roche - Gilead - Janssen - AbbVie - Merck Sharp & Dohme: Payment directly from commercial firms for lecture(s), including service on speakers’bureaus Chow, Felicia Self: AbbVie: Other Colby, Donn Self: Roche Molecular Systems: Grants/grants pending Institution: Thai Red Cross AIDS Research Center: Merck: Provision of medicines, equipment, or administrative support; Cooper Human Systems: Grants/grants pending; Crucell: Grants/grants pending; Provision of medicines, equipment, or administrative support; Gilead: Provision of medicines, equipment, or administrative support Cooper, David Self: Gilead: Other;ViiV Healthcare: Other; Merck Sharp & Dohme: Other Institution: UNSW: Gilead: Other;ViiV Healthcare: Other; Merck Sharp 7 Dohme: Other Cowan, Frances Self: Gilead Sciences: Provision of medicines, equipment, or administrative support Crowley, Jeffrey Self: Gilead Sciences: Grants/grants pending; AbbVie: Grants/grants pending; Bristol Myers Squibb: Payment directly from commercial firms for lecture(s), including service on speakers’bureaus;WebMD: Payment directly from commercial firms for lecture(s), including service on speakers’bureaus Cuffe, Robert Self: ViiV Healthcare: Employment; GlaxoSmithKline: Stock/stock options; Other:ViiV markets some of the drugs analyzed in the presentation. GSK has a majority shareholding inViiV Custodio, Joseph Self: Gilead Sciences, Inc.: Stock/stock options Institution: Gilead Sciences, Inc.: Gilead Sciences, Inc.: Employment Cuzin, Lise Self: Board Membership;ViiV Healthcare: Board Membership

Institution: MRC-ClinicalTrials Unit at UCL: Janssen: Provision of medicines, equipment, or administrative support; AbbVie: Provision of medicines, equipment, or administrative support; GSK: Provision of medicines, equipment, or administrative support; Gilead: Provision of medicines, equipment, or administrative support; Merck: Provision of medicines, equipment, or administrative support; Abbot Labs: Provision of medicines, equipment, or Institution: S. Gerardo Hospital, Infectious Diseases Unit: AbbVie/Astellas/BMS: Grants/grants pending; Janssen/MSD: Grants/grants pending; Boehringer/Gilead: Grants/grants pending;ViiV Healthcare: Grants/grants pending; Novartis: Grants/grants pending; Roche: Grants/grants pending Basilissi, Matteo Institution: Department of Health Sciences, Clinical of Infectious Diseases andTropical Medicine, San Paolo Hospital, Milan : Gilead Sciences Srl: Grants/grants pending Baugher, Amy Self: Oak Ridge Institute for Science and Education: Employment Benarous, Richard Self: Benarous Richard: BiodimMutabilis: Employment Institution: BiodimMutabilis: Board Membership Bennett, Sean Self: Gilead Sciences Inc: Employment ; Other: Clinical trial agreement Berenguer, Juan Self: AbbVie: Consulting or advisor fee; BMS: Consulting or advisor fee; Gilead: Consulting or advisor fee; Janssen: Consulting or advisor fee; MSD: Consulting or advisor fee; ViiV: Grants/grants pending Berg, Michael Self: Abbott Laboratories: Employment Bernardino, Jose Self: Gilead: Consulting or advisor fee;ViiV healthcare: Consulting or advisor fee; MSD: Consulting or advisor fee; Janssen: Consulting or advisor fee; BMS: Consulting or advisor fee administrative support Bandera, Alessandra Self: Gilead: Grants/grants pending

Disclosure Information

652

CROI 2015